# KG Investments

> KG Investments is a VC fund in Scottsdale backing Software and Health Care. See 16 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Scottsdale, United States
- Total investments: 16
- Last investment: Jul 2021
- Lead investor: 19%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/kaplan-group-investments/
- Website: http://www.kginvest.net/

KG Investments is a private family office fund focused on investing in technology companies through direct investments and secondary loans. This approach is guided by its extensive background of building and investing in technology-related companies over the last 20 years.KG Investments also invests in uncorrelated professionally managed Hedge& Private Equity funds as a Limited Partner looking for unique differentiated opportunities. It was founded in 2006 and is based in Scottsdale, Arizona.

## Contacts

5 contacts available for KG Investments. Shizune tracks 2 team members at KG Investments. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/kg-investments?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Software | 4 | 25% |
| Health Care | 3 | 19% |
| Information Technology | 3 | 19% |
| Mobile | 2 | 13% |
| FinTech | 2 | 13% |

46 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 4 | 25% |
| Funding Round | 4 | 25% |
| Post-IPO Equity | 3 | 19% |
| Venture - Series Unknown | 2 | 13% |
| Series A | 1 | 6% |

7 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 10 | 63% |
| China | 1 | 6% |
| Canada | 1 | 6% |
| Germany | 1 | 6% |
| United Kingdom | 1 | 6% |

6 countries tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Allan Kaplan | Managing Partner & Founder | 9 | https://shizune.co/investors/profile/allan-kaplan |
| Vicki Wittie | Chief Financial Officer | 0 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Owlet Baby Care | The Owlet Baby Monitor is a proactive health monitor for sleeping infants that allows parents to view their child's vital signs in real time. Owlet will alert the parent if there are low blood oxygen and heart rate levels giving parents peace of mind knowing that their baby is watched over. | $130M | Post-IPO Equity | Jul 16, 2021 |  |
| Rubrik | Rubrik offers live data access for recovery and application development by fusing enterprise data management with web-scale IT and eliminating backup software. This marks the end of a decade-long innovation drought in backup and recovery, the backbone of IT. Within minutes, businesses can manage the explosion of data across private and publicclouds. | $10.8M | Secondary Market | May 24, 2021 |  |
| Tenstorrent | Tenstorrent is enabling a new era in AI and deep learning with its breakthrough processor architecture and software. The company’s mission is to deliver orders of performance and efficiency for AI workloads from the data center to the edge of the Cloud by co-designing hardware, software, and AI algorithms with their technology.Tenstorrent’sarchitecture scales from datacenter servers to IoT devices with improved efficiency, flexibility, programmability compared to legacy accelerators including CPUs, GPUs, FPGAs, and TPU-type processors. It is developed by their team with expertise in computer architecture, hardware design and verification, systems engineering, compilers, software development, and machine learning algorithms.Tenstorrent is backed by Venture Capital firms including Real Ventures and Eclipse Venture Capital, as well as prominent industry luminaries. | $200M | Series C | May 20, 2021 |  |
| Applied Molecular Transport | Applied Molecular Transport Inc. is a clinical-stage biopharmaceutical company leveraging its proprietary technology platform to design and develop a pipeline of novel oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. AMT’s proprietary technology platform allows it to exploit existing naturalcellular trafficking pathways to facilitate the active transport of therapeutic payloads across the intestinal epithelium (IE) barrier. Active transport is an efficient mechanism that uses the cell’s own machinery to transport materials across the IE barrier. AMT believes that its ability to exploit this mechanism is a key differentiator of its approach. AMT is developing oral biologic product candidates in patient-friendly tablet and capsule forms that are designed for either targeting local gastrointestinal (GI) tissue or entering systemic circulation to precisely address the relevant biology of a disease. AMT is building a portfolio of oral product candidates based on its technology platform including its lead product candidate, AMT-101, an oral GI-selective interleukin 10 that has completed a Phase 1b clinical trial in patients with ulcerative colitis (UC). AMT further plans to initiate Phase 2 clinical trials of AMT-101 in UC and related inflammatory indications. AMT’s technology platform enables it to design and develop various oral biologic therapeutic modalities, such as peptides, proteins, full-length antibodies, antibody fragments, and RNA therapeutics, with potentially significant advantages over existing marketed and development-stage drugs. | $120.8M | Post-IPO Equity | Mar 31, 2021 |  |
| Hastee | Hastee is an employee benefit that companies can offer to their workforce. It empowers employees to receive their earned pay immediately to increase their choice and financial wellbeing. Companies profit from the improved productivity, engagement, recruitment & retention of their workforce, with zero cost or impact on company cash-flow.Thecompany was founded in 2017 and is headquartered in London, England. |  | Venture - Series Unknown | Jan 01, 2021 |  |
| Nebula Scientific | Nebula Scientific offers industry experts the to bring innovation to the nutraceutical space by using next-generation technologies. They provide superior methods of active ingredient delivery. They offer comprehensive solutions for devices, nutritional supplement formulations, retail packaging, branding, and global logistics. |  | Venture - Series Unknown | Jan 01, 2021 |  |
| Ant Group | Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. They strive to enable all consumers and small businesses to have equal access to financial and other services that are inclusive, green and sustainable. |  |  | Jan 01, 2020 |  |
| Lucira Health | Lucira Health is a medical technology company focused on the development and commercialization of transformative and innovative infectious disease test kits. Lucira has developed a testing platform that produces centralized-laboratory-accurate molecular testing in a single-use and consumer-friendly test kit that is powered by two AA batteries andfits in the palm of a hand. Lucira designed its test kits to provide accurate, reliable and on-the-spot molecular test results anywhere and at any time. The LUCIRA COVID-19 All-In-One Test Kit is designed to provide a clinically relevant COVID-19 result within 30 minutes from sample collection. | $15M | Series B | Aug 05, 2019 |  |
| OMEICOS Therapeutics | OMEICOS Therapeutics is developing a novel, first-in-class, small molecule utilizing a new Mode of Action. OMEICOS' novel therapeutic strategy is based upon the discovery of natural metabolites of omega-3 fatty acids that mediate a strong anti-arrhythmic effect. In contrast to all other anti-arrhythmic drugs, OMEICOS' substances activatean endogenous cardio-protective signaling pathway that not only stabilizes the heart rhythm but shall provide curative effects to the diseased organ by preventing its electrical and structural remodeling. | $18.6M | Series C | Nov 02, 2018 |  |
| Ant Group | Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. They strive to enable all consumers and small businesses to have equal access to financial and other services that are inclusive, green and sustainable. | $14B | Series C | Jun 08, 2018 |  |

10 of 16 investments shown.

## Co-investors
- [Eclipse](https://shizune.co/investors/profile/eclipse-ventures) — VC Fund, 2 deals together
- [Fidelity](https://shizune.co/investors/profile/fidelity-investments) — VC Fund, 2 deals together
- [Fidelity](https://shizune.co/investors/profile/fidelity-management-and-research-company) — VC Fund, 2 deals together
- [Almaz Capital](https://shizune.co/investors/profile/almaz-capital) — VC Fund, 1 deal together
- [Austin Ventures](https://shizune.co/investors/profile/austin-ventures) — VC Fund, 1 deal together
- [Avalon Ventures](https://shizune.co/investors/profile/avalon-ventures) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does KG Investments invest in?

KG Investments invests primarily in Software, Health Care and Information Technology startups, most often at Series C and Funding Round stage. Most of the 16 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact KG Investments?

Public channels for KG Investments include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at KG Investments?

The team at KG Investments includes Allan Kaplan (Managing Partner & Founder) and Vicki Wittie (Chief Financial Officer). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co